



Published in final edited form as:

RSC Chem Biol. 2020 October 1; 1(4): 273–280. doi:10.1039/d0cb00075b.


Long-range PEG Stapling: Macrocyclization for Increased Protein Conformational Stability and Resistance to Proteolysis

Qiang Xiao, Dallin S. Ashton, Zachary B. Jones, Katherine P. Thompson, Joshua L. Price
Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, United States

Abstract

We previously showed that long-range stapling of two Asn-linked O-allyl PEG oligomers via olefin metathesis substantially increases the conformational stability of the WW domain through an entropic effect. The impact of stapling was more favorable when the staple connected positions that were far apart in primary sequence but close in the folded tertiary structure. Here we validate these criteria for identifying new stabilizing PEG-stapling sites within the WW domain and the SH3 domain, both β -sheet proteins. We find that stapling via olefin metathesis vs. the copper(I)-catalyzed azide/alkyne cycloaddition (CuAAC) results in similar energetic benefits, suggesting that olefin and triazole staples can be used interchangeably. Proteolysis assays of selected WW variants reveal that the observed staple-based increases in conformational stability lead to enhanced proteolytic resistance. Finally, we find that an intermolecular staple dramatically increases the quaternary structural stability of an α -helical GCN4 coiled-coil heterodimer.

Graphical Abstract



Introduction

Macrocyclization is one of the most useful strategies for increasing the stability of peptides, proteins, and binding complexes in supramolecular chemistry and chemical biology.^{1–4} Covalent constraints can preorganize a peptide or protein into a shape that resembles its folded or bound conformation, thereby “pre-paying” part of the cost associated with folding or binding, through a combination of entropic and enthalpic effects.^{1–4} Disulfide bonds can

jlprice@chem.byu.edu.

Conflicts of Interest

There are no conflicts of interest to declare.

Electronic Supplementary Information

Experimental methods; compound characterization data, including mass spectra, HPLC chromatograms, and NMR spectra where applicable; CD spectra; global fits of variable temperature CD data; proteolysis assay data.

play this role in synthetic peptides or proteins; ⁵⁻⁹ however, correct disulfide connectivity sometimes requires creative protecting group strategies and the disulfides themselves are not stable in reducing environments, making disulfide-stapled peptides and proteins unsuitable as therapeutics with intracellular targets. Efforts to address these limitations have led to a growing number of chemoselective ligation reactions¹⁰ (i.e. stapling reactions) that are tolerant of water and are selective for a particular reactive partner in the presence of diverse biological nucleophiles and electrophiles. Thiol alkyl-¹¹⁻¹⁵ or arylation¹⁶ takes advantage of the nucleophilicity of Cys but results in thioether staples that are stable to reducing conditions. For example, azobenzene-linked bis-electrophiles can provide photoisomerization-based conformational control.^{17, 18} Tris-electrophiles can connect three different Cys residues,^{19, 20} thereby stabilizing existing tertiary structures²¹ or providing access to new macrocyclic topologies not possible with disulfides alone.²² These Cys-centric approaches are generally limited to side-chain/side-chain crosslinks; in contrast, other approaches facilitate stapling in both side-chain and backbone contexts.²³ For example, lactam staples can be prepared via conventional peptide coupling chemistry²⁴⁻²⁹ or by diverse chemoselective strategies, including the Ugi reaction;^{30, 31} direct thioester aminolysis;³² native chemical ligation;³³⁻³⁵ KAHA ligation;³⁶ traceless Staudinger ligation;³⁷ a variety of enzymatic methods.³⁸⁻⁴⁰ Other creative stapling strategies include C-H activation;⁴¹⁻⁴³ the Petasis reaction;⁴⁴ the Glaser reaction;⁴⁵ oxime^{46, 47} or hydrazone⁴⁸ formation; the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC);⁴⁹⁻⁵⁵ and olefin metathesis.⁵⁶⁻⁶¹

We are interested in understanding the origin and determinants of protein stabilization via macrocyclization/stapling in diverse structural contexts. The WW domain is a triple-stranded antiparallel β -sheet protein;⁶² positions 16 and 19 within WW are close in sequence and in tertiary structure: both are located within a reverse turn that connects first and second β -strands. Each is also a location where Asn-PEGylation is substantially stabilizing.⁶³ In WW variant **16/19-o23**, residues 16 and 19 are occupied by Asn residues that have been modified with two- and three-unit O-allyl PEGs, respectively (Figure 1).⁶⁴ Bis-PEGylated **16/19-o23** is -0.75 ± 0.02 kcal/mol more stable than its non-PEGylated counterpart **16/19-00**; Crosslinking of the O-allyl PEGs via olefin metathesis results in stapled variant **s16/19-o23**, which is -0.29 ± 0.02 kcal/mol more stable than **16/19-o23**. This stabilizing change in folding free energy (ΔG) comes from a favorable change in entropy (i.e., $-\Delta T \Delta S$), partially offset by an unfavorable change in enthalpy (ΔH), an observation that is consistent with the anticipated impact of macrocyclization on protein folding as described above. However, the ΔG associated with stapling (-0.29 ± 0.02 kcal/mol; compare **s16/19-o23** vs. **16/19-o23**) is much smaller than the ΔG associated with bis-PEGylation (-0.75 ± 0.02 kcal/mol; compare **s16/19-o23** vs. **16/19-00**). Incorporating PEGs of longer and shorter lengths within this staple failed to improve the observed staple-based stabilization.⁶⁴

We wondered whether the limited energetic benefits of stapling positions 16 and 19 reflected their proximity in primary sequence (3 residues apart) as well as in tertiary structure (4.0 Å between C β 's of these positions in the crystal structure of the parent WW domain⁶⁵): positions 16 and 19 may be similarly close in both folded and unfolded conformations of non-stapled WW, such that covalently linking them together has only marginal benefits. We

hypothesized that stapling between positions that are farther apart in primary sequence but still relatively close in the folded tertiary structure would have a more favorable impact. Position 32 at the C-terminal end of the third β -strand in WW is a stabilizing Asn-PEGylation site⁶³; it is on the same face of WW as is position 16 (9.4 Å between C β 's of these positions), but is much farther from position 16 in primary sequence (i.e. 16 residues) than is position 19. Bis-PEGylated WW variant **16/32-o44** (with Asn-linked four-unit O-allyl PEGs at positions 16 and 32) is -0.40 ± 0.05 kcal/mol more stable than non-PEGylated **16/32-00**. Olefin-stapled **s16/32-o44** is -1.11 ± 0.04 kcal/mol more stable than non-stapled **16/32-o44** due to a favorable entropic effect offset by a smaller unfavorable change in enthalpy.⁶⁴ The ΔG and $-\Delta T \Delta S$ values associated with stapling of positions 16 and 32 are much more favorable than we observed for positions 16 and 19, presumably because the staple increases the proximity of positions 16 and 32 in the unfolded ensemble, thereby reducing the entropic cost of their proximity in the folded conformation.⁶⁴

These published observations suggest that substantial separation in primary sequence but proximity in tertiary structure are important criteria for identifying stabilizing PEG-stapling sites within proteins. Here we validate these criteria by identifying new PEG-stapling sites within WW and the Src SH3 domain. We also explore the stabilizing impact of stapling via olefin metathesis vs. CuAAC at selected locations within WW and demonstrate that staple-based stabilization is associated with enhanced resistance to proteolytic degradation. Finally, we show that intermolecular PEG stapling increases the quaternary structural stability of an α -helical GCN4 coiled-coil heterodimer.

Results and Discussion

Positions 14 and 30 in WW are 16 residues apart in primary sequence and occupy the same face of WW (11.7 Å between C β 's of these positions⁶⁵), similar to the relationship between positions 16 and 32. We wondered whether PEG stapling of positions 14 and 30 would be similarly stabilizing. A potential complicating issue is our previous observation that individual Asn-PEGylation has a minimal impact on WW conformational stability at position 14 and at position 30, whereas individual Asn-PEGylation is stabilizing at position 16 and position 32.⁶³ We wondered whether PEG stapling of positions 14 and 30 would continue to be stabilizing in the absence of strong PEG-based stabilization at these positions. Interestingly, bis-PEGylated WW variant **14/30-o55** (with Asn-linked five-unit O-allyl PEGs at positions 14 and 30) is -0.34 ± 0.02 kcal/mol more stable than its non-PEGylated counterpart **14/30-00**. Olefin-stapled **s14/30-o55** is -0.49 ± 0.05 kcal/mol more stable than **14/30-o55**, a more favorable value than we observed previously for stapling of positions 16 and 19 ($\Delta G = -0.29 \pm 0.02$ kcal/mol), but less favorable than for stapling of positions 16 and 32 ($\Delta G = -1.11 \pm 0.04$ kcal/mol). The small magnitude and high uncertainty in the values of ΔH and $-\Delta T \Delta S$ for **s14/30-o55** vs. **14/30-o55** (see Table 1) make it difficult to assess the entropic vs. enthalpic origin of the staple-based stabilization at positions 14 and 30. However, these results suggest that close proximity in tertiary structure and substantial separation in primary sequence are the most important criteria for identifying locations where PEG stapling will be stabilizing, though optimal staple-based stabilization may depend moderately on the intrinsic impact of PEGylation at the prospective staple sites. It is also noteworthy that the relatively flexible linkers (containing 5–10 ethylene oxide units)

within **s16/19-o23**, **s16/32-o44**, and **s14/30-o55** can provide such a substantial level (-0.3 to -1.2 kcal/mol) of staple-based stabilization.

We next sought to apply these criteria to a larger and more structurally complex protein. We previously found that Asn-PEGylation at position 20 within the Src SH3 domain (hereafter called SH3) substantially increases the conformational stability of the PEGylated SH3 variant relative to its non-PEGylated counterpart.⁶³ Positions 20 and 37 occur within two different unstructured loops in SH3 and are far apart in primary sequence (i.e. 17 residues); however, they occupy the same face of folded SH3 tertiary structure (17.0 Å between C β 's of these positions in the crystal structure of the parent SH3⁶⁶). We hypothesized that metathesis-based PEG stapling of these two positions would increase the conformational stability of SH3. Accordingly, we prepared bis-PEGylated SH3 variant **20/37-o44**, in which positions 20 and 37 are each occupied by four-unit Asn-linked O-allyl PEGs. The thermal unfolding behavior of variant **20/37-o44** was not consistent with two-state folding, which precluded detailed analysis of its conformational stability. In contrast, olefin-stapled variant **s20/37-o44** ($T_m = 76.0 \pm 0.8$ °C) is -0.93 ± 0.07 kcal/mol more stable than non-PEGylated **20/37-00** ($T_m = 61.1 \pm 0.3$ °C). The unusual thermal unfolding behavior of **20/37-o44** vs. **20/37-00** prevents us from determining how much of the favorable AAG value for **s20/37-o44** vs. **20/37-00** comes from bis-PEGylation vs. olefin stapling. However, these observations hint at the intriguing potential for olefin-based PEG stapling to rescue two-state folding and restore conformational stability to proteins with unusual thermal unfolding behavior.

We next wondered whether stapling of Asn-linked PEGs via CuAAC (i.e., click stapling) would provide levels of stabilization similar to what we observed previously for olefin stapling. To explore this possibility, we prepared WW variant **16/32-c44**, in which an O-propargyl four-unit Asn-PEG occupies position 16, with an azide-terminated four-unit Asn-PEG at position 32 (Figure 1). Click stapling results in variant **s16/32-c44**, which is -1.24 ± 0.03 kcal/mol more stable than its non-stapled counterpart. Similarly, click-stapled WW variant **s14/30-c44** is -0.61 ± 0.02 kcal/mol more stable than non-stapled **14/30-c44** (see Table 1). These results demonstrate that the impact of stapling is tolerant of variations in the nature of the staple, with click stapling slightly more stabilizing than olefin stapling at the positions we investigated.

We previously showed that PEG-based increases in WW conformational stability are associated with increased levels of protection from proteolysis. We wondered whether this would be true for PEG-stapled WW variants. We explored this possibility by exposing 50 μ M solutions of WW variants **16/19-00**, **16/19-o23**, **s16/19-o23**, **16/32-00**, **16/32-o44**, and **s16/32-o44** to proteinase K (17 μ g/mL) and monitoring the amount of full-length protein remaining in solution at regular intervals by analytical HPLC. We fit the resulting data to a monoexponential decay function to obtain apparent proteolysis rate constants. The results of this analysis are shown in Figure 2A,B. PEGylated olefin-stapled variant **s16/19-o23** is more resistant to proteolysis than its PEGylated but non-stapled counterpart **16/19-o23**, which is, in turn, more resistant to proteolysis than non-PEGylated non-stapled **16/19-00**. Similarly, PEGylated olefin-stapled variant **s16/32-o44** is more resistant to proteolysis than PEGylated but non-stapled **16/32-o44**, which is more resistant to proteolysis than non-stapled non-PEGylated **16/32-00**. For each variant, we calculated a proteolytic resistance factor r , which

is the ratio between the apparent rate constant for a PEGylated olefin-stapled variant or its PEGylated but non-stapled counterpart relative to the parent non-PEGylated non-stapled variant. Variants with smaller values of r are more resistant to proteolysis than the corresponding parent variant. We then plotted the natural logarithm of r against the corresponding difference in free energy for the compound relative to its non-PEGylated non-stapled parent variant (Figure 2C). $\ln r$ varies linearly with ΔG as indicated by least-squares regression ($R^2 = 0.996$), indicating that more stabilized WW variants experience greater levels of proteolytic resistance, independent of whether the increased stability comes primarily from PEGylation, olefin-stapling, or a combination of the two.

In the examples described above, we installed olefin or click staples between two positions in the same monomeric protein (WW or SH3). We wondered whether the extent of stabilization observed in these monomeric systems might extend to intermolecular staples between subunits of quaternary structure. We explored this possibility within an α -helical coiled coil, one of the best understood tertiary/quaternary structural motifs in proteins.^{67–69} Coiled-coil primary sequence is comprised of a seven-residue repeating unit called a heptad; the first and fourth residues within this unit (i.e. positions a and d of an $abcdefg$ heptad) are typically occupied by nonpolar residues, with charged residues at e and g positions and polar or charged residues at b , c , and f positions.^{70, 71} Burial of non-polar residues at a and d positions provides the major driving force for folding; the shape of these a and d residues can specify coiled-coil oligomerization state (dimer, trimer, tetramer, etc.).^{72–77} Complementary electrostatic interactions between an e residue on one helix and an g residue on the other provide specificity for homo- vs. heterooligomerization^{78–81} and for parallel vs. antiparallel orientation.^{82–84}

Others have already begun to apply intermolecular stapling to α -helical coiled coils, but with limited focus on the thermodynamic consequences of stapling. Arora and coworkers previously used CuAAC to install a bis-triazole staple in place of native interhelical e/g and e/e salt bridges within antiparallel⁸⁵ and parallel⁸⁶ coiled-coil heterodimers comprised of two nine-residue peptides. The staple enabled a surprisingly large extent of helicity at such a short oligomer length, though its precise energetic contribution to coiled-coil conformational stability was not assessed. Karlström and coworkers⁸⁷ installed a single interhelical staple between a Cys residue and a chloroacetamide-modified Lys within a monomeric three-helix bundle HER2 affibody. Of the three locations they tested, only one Cys-Lys staple led to a substantial increase in conformational stability relative to a non-stapled reference compound (i.e. a 5 °C increase in melting temperature); the origin of this disparity was not explored in detail. Jiang, Liu, and coworkers⁸⁸ formed an isopeptide bond between each of three identical e -position Glu residues within a helix-bundle trimer and a g -position Lys from the previous heptad on an adjacent helix. The resulting triply stapled helix bundle had no cooperative thermal unfolding transition below 90 °C and was resistant to aggregation and proteolysis, though no comparison with its non-stapled counterpart was reported.

We explored the quantitative impact of interhelical stapling on α -helical coiled-coil conformational stability in the context of a previously characterized coiled-coil tertiary structure based on the GCN4 homodimer, in which acidic peptide **A** and basic peptide **B** are covalently connected via a disulfide bond to form parallel monomeric coiled coil **A/B**.⁸⁹ In

disulfide-bound **A/B**, *e*-position Glu residues in peptide **A** engage in interhelical salt bridges with *g*-position Lys residues in peptide **B** (similarly, *e*-position Lys residues in **B** interact with *g*-position Glu residues in **A**). Each *e/g* pair is oriented such that a *g* residue on one helix is close to the *e* residue from the previous heptad on the other helix. For example, Oe2 of *e*-position Glu27 in **A** is only 4.3 Å from N ζ of *g*-position Lys22' in **B** but is 9.7 Å from N ζ of *g*-position Lys29'. Whereas Arora^{85, 86} and Liu⁸⁸ used stapling to replace *e/g* salt bridges within parallel coiled coils, we wondered how a longer-range staple might influence coiled-coil conformational stability.

We addressed this question by preparing peptide **27-c4** (a variant of acidic peptide **A** in which *e*-position Glu27 has been replaced with an azide-terminated Asn-PEG comprised of four ethylene oxide units) and peptide **29'-c0** (a variant of basic peptide **B** in which *g*-position Lys29 has been replaced with propargylglycine), which are shown in Figure 3. We chose these positions because Glu27 in **A** and Lys29 in **B** are not involved in a salt bridge with each other in the parent disulfide-bound coiled-coil monomer **A/B**. We mixed **27-c4** and **29'-c0** in an equimolar ratio in the presence of air to form monomeric disulfide-bound **d27/29'-c40**; we then prepared its click- stapled counterpart **sd27/29'-c40** via CuAAC. CD data for **d27/29'-c40** and **sd27/29'-c40** are consistent with the formation of an α -helical coiled-coil tertiary structure. The disulfide bond makes both variants are both monomeric even though one is stapled and the other is not; this facilitates direct comparison of their folding free energies. In the presence of 4 M GdnHCl, triazole-stapled **sd27/29'-c40** ($T_m = 48.2 \pm 0.1$ °C) is -0.65 ± 0.01 kcal/mol more stable than non-stapled **d27/29'-c40** ($T_m = 41.1 \pm 0.2$ °C, see Table 1); we used 4 M GdnHCl because these variants were too stable to characterize via variable temperature CD in the absence of denaturant (i.e., their thermal unfolding transitions were not complete even at 94 °C). These results indicate that a long-range interhelical staple between non-interacting *e* and *g* positions can increase the conformational stability of a coiled coil to a similar extent as we observed above for click and olefin staples within the β -sheet-rich WW and SH3 domains.

We wondered how much this interhelical staple would stabilize a heterodimeric coiled-coil quaternary structure in which the individual helices were not disulfide-bound. Accordingly, we prepared peptides **27A-c4** and **29A'-c0**, variants of **27-c4** and **29'-c0**, respectively, in which Ala occupies position 33 instead of Cys. Peptides **27A-c4** and **29A'-c0** combine in a 1:1 ratio to form noncovalent heterodimeric coiled coil **27/29'-c40**; the CD spectrum of **27/29'-c40** is consistent with coiled-coil quaternary structure; variable temperature CD data in the presence of 0.5 M GdnHCl indicate that **27/29'-c40** undergoes a cooperative thermal unfolding transition with $T_m = 34.8$ °C. Click stapling converts noncovalent heterodimer **27/29'-c40** into stapled monomeric **s27/29'-c40**, which has a similar CD spectrum, and undergoes a cooperative thermal unfolding transition with $T_m = 82.0 \pm 0.2$ °C. The folding free energies of **27/29'-c40** and **s27/29'-c40** are not directly comparable because of their distinct association states: the ΔG of noncovalent heterodimer **27/29'-c40** is concentration dependent, whereas the ΔG of stapled monomeric **s27/29'-c40** is not. However, stapling increases the melting temperature of **s27/29'-c40** by 49.2 °C relative to noncovalent heterodimer **27/29'-c40** in 0.5 M GdnHCl, suggesting that the stabilizing impact of intermolecular interhelical stapling is substantial.

Conclusion

Here we have shown that PEG stapling enhances WW conformational stability best when the staple sites are distant in primary sequence, close in tertiary structure, and are each individually stabilized by Asn-PEGylation. We applied these criteria to the SH3 domain, where PEG stapling increased the stability of the stapled variant by -0.9 kcal/mol relative to its non-PEGylated non-stapled counterpart. We found that staple-based stabilization is associated with increased proteolytic resistance and is tolerant of variation in linker chemistry, with triazole and olefin linkers providing similar energetic benefits. We also found that an intermolecular PEG staple between non-interacting *e*- and *g*-positions in a GCN4-derived α -helical coiled-coil heterodimer dramatically increases the stability of the stapled coiled-coil relative to its non-stapled counterpart.

We previously found that staples comprised of PEGs shorter than a certain threshold can actually decrease protein conformational stability, presumably because the PEGs are too short to accommodate the distance between the staple sites in the folded tertiary structure.⁶⁴ We originally expected longer PEG staples to have a less stabilizing impact; we reasoned that a longer PEG would not be as effective at promoting folding by restricting the freedom of the staple sites. Our results were not consistent with this hypothesis: we found that incremental increases to PEG length beyond the minimum threshold do not dramatically change the stabilizing impact of stapling or its entropic origin.⁶⁴ In agreement with these previous results, we herein observed substantial levels of entropy-derived stabilization despite the length of the PEG staples: eight ethylene oxide units in **s16/32-o44**, **s16/32-c44**, and **20/37-o44**; ten in **14/30-o55**; and four in **s27/29'-c40**. It is possible that the length and flexibility of the PEG staple is responsible for its versatility in the secondary, tertiary, and quaternary structural contexts investigated here (β -sheet tertiary structures, α -helical coiled-coil quaternary structure). This versatility should be useful in applying PEG stapling to the stabilization of therapeutic proteins. In any case, it will be interesting to see whether the stabilizing impact of longer staples is a unique feature of PEG stapling or whether it also extends to stapling with other linkers (e.g., hydrocarbons).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by NIH grant number 2 R15 GM116055-02.

References

1. Cram DJ, *Angew. Chem. Int. Ed*, 1986, 25, 1039–1057.
2. Lehn JM, *Angew. Chem. Int. Ed*, 1988, 27, 89–112.
3. Pedersen CJ, *Angew. Chem. Int. Ed*, 1988, 27, 1021–1027.
4. Hruby VJ, *Life Sci*, 1982, 31, 189–199. [PubMed: 6126794]
5. Jackson DY, King DS, Chmielewski J, Singh S and Schultz PG, *J. Am. Chem. Soc*, 1991, 113, 9391–9392.

6. Gongora-Benitez M, Tulla-Puche J and Albericio F, *Chem. Rev.*, 2014, 114, 901–926. [PubMed: 24446748]
7. Betz SF, *Protein Sci.*, 1993, 2, 1551–1558. [PubMed: 8251931]
8. Zhang T, Bertelsen E and Alber T, *Nat. Struct. Biol.*, 1994, 1, 434–438. [PubMed: 7664061]
9. Dombkowski AA, Sultana KZ and Craig DB, *FEBS Lett.*, 2014, 588, 206–212.
10. Chow HY, Zhang Y, Matheson E and Li X, *Chem. Rev.*, 2019, 119, 9971–10001. [PubMed: 31318534]
11. Brunel FM and Dawson PE, *Chem. Commun.*, 2005, DOI: 10.1039/B419015G, 2552–2554.
12. Zhang F, Sadvoski O, Xin SJ and Woolley GA, *J. Am. Chem. Soc.*, 2007, 129, 14154–14155. [PubMed: 17960932]
13. Bionda N, Cryan AL and Fasan R, *ACS Chem. Biol.*, 2014, 9, 2008–2013. [PubMed: 25079213]
14. Peraro L, Siegert TR and Kritzer JA, *Methods Enzymol.*, 2016, 580, 303–332. [PubMed: 27586339]
15. Moore EJ, Zorine D, Hansen WA, Khare SD and Fasan R, *Proc. Natl. Acad. Sci. USA*, 2017, 114, 12472–12477. [PubMed: 29109284]
16. Rojas AJ, Zhang C, Vinogradova EV, Buchwald NH, Reilly J, Pentelute BL and Buchwald SL, *Chem. Sci.*, 2017, 8, 4257–4263. [PubMed: 29081961]
17. Flint DG, Kumita JR, Smart OS and Woolley GA, *Chem. Biol.*, 2002, 9, 391–397. [PubMed: 11927265]
18. Woolley GA, *Acc. Chem. Res.*, 2005, 38, 486–493. [PubMed: 15966715]
19. Heinis C, Rutherford T, Freund S and Winter G, *Nat. Chem. Biol.*, 2009, 5, 502–507. [PubMed: 19483697]
20. Heinis C and Winter G, *Curr. Opin. Chem. Biol.*, 2015, 26, 89–98. [PubMed: 25768886]
21. Pelay-Gimeno M, Bange T, Hennig S and Grossmann TN, *Angew. Chem. Int. Ed.*, 2018, 57, 11164–11170.
22. Dang B, Wu H, Mulligan VK, Mravic M, Wu Y, Lemmin T, Ford A, Silva DA, Baker D and DeGrado WF, *Proc. Natl. Acad. Sci. USA*, 2017, 114, 10852–10857. [PubMed: 28973862]
23. Horne WS and Grossmann TN, *Nat. Chem.*, 2020, 12, 331–337. [PubMed: 32029906]
24. Chorev M, Roubini E, Mckee RL, Gibbons SW, Goldman ME, Caulfield MP and Rosenblatt M, *Biochemistry*, 1991, 30, 5968–5974. [PubMed: 1646005]
25. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP and Spatola AF, *Proc. Natl. Acad. Sci. U.S.A.*, 2003, 100, 11273–11278. [PubMed: 13679575]
26. Fujimoto K, Oimoto N, Katsuno K and Inouye M, *Chem. Commun.*, 2004, DOI: 10.1039/B403615H, 1280–1281.
27. Shepherd NE, Abbenante G and Fairlie DP, *Angew. Chem. Int. Ed.*, 2004, 43, 2687–2690.
28. Vaz E, Pomerantz WC, Geyer M, Gellman SH and Brunsveld L, *Chembiochem*, 2008, 9, 2254–2259. [PubMed: 18756554]
29. Kajino M, Fujimoto K and Inouye M, *J. Am. Chem. Soc.*, 2011, 133, 656–659. [PubMed: 21174399]
30. Vasco AV, Perez CS, Morales FE, Garay HE, Vasilev D, Gavin JA, Wessjohann LA and Rivera DG, *J. Org. Chem.*, 2015, 80, 6697–6707. [PubMed: 26030840]
31. Vasco AV, Méndez Y, Porzel A, Balbach J, Wessjohann LA and Rivera DG, *Bioconjugate Chem.*, 2019, 30, 253–259.
32. Wang C, Li X, Yu F, Lu L, Jiang X, Xu X, Wang H, Lai W, Zhang T, Zhang Z, Ye L, Jiang S and Liu K, *Sci. Rep.*, 2016, 6, 32161. [PubMed: 27562370]
33. Zhang L and Tam JP, *J. Am. Chem. Soc.*, 1997, 119, 2363–2370.
34. Camarero JA and Muir TW, *Chem. Commun.*, 1997, DOI: 10.1039/A702083J, 1369–1370.
35. Camarero JA and Muir TW, *J. Am. Chem. Soc.*, 1999, 121, 5597–5598.
36. Rohrbacher F, Zwicky A and Bode JW, *Chem. Sci.*, 2017, 8, 4051–4055. [PubMed: 28580120]
37. Kleineweischede R and Hackenberger CP, *Angew. Chem. Int. Ed.*, 2008, 47, 5984–5988.
38. Antos JM, Popp MW, Ernst R, Chew GL, Spooner E and Ploegh HL, *J. Biol. Chem.*, 2009, 284, 16028–16036. [PubMed: 19359246]

39. Nguyen GKT, Kam A, Loo S, Jansson AE, Pan LX and Tam JP, *J. Am. Chem. Soc.*, 2015, 137, 15398–15401. [PubMed: 26633100]
40. Luo H, Hong SY, Sgambelluri RM, Angelos E, Li X and Walton JD, *Chem. Biol.*, 2014, 21, 1610–1617. [PubMed: 25484237]
41. Mendive-Tapia L, Preciado S, Garcia J, Ramon R, Kielland N, Albericio F and Lavilla R, *Nat. Commun.*, 2015, 6, 7160. [PubMed: 25994485]
42. Noisier AFM, Garcia J, Ionut IA and Albericio F, *Angew. Chem. Int. Ed.*, 2017, 56, 314–318.
43. Lorion MM, Kaplaneris N, Son J, Kuniyil R and Ackermann L, *Angew. Chem. Int. Ed.*, 2019, 58, 1684–1688.
44. Ricardo MG, Llanes D, Wessjohann LA and Rivera DG, *Angew. Chem. Int. Ed.*, 2019, 58, 2700–2704.
45. Cistrone PA, Silvestri AP, Hintzen JCJ and Dawson PE, *ChemBioChem*, 2018, 19, 1031–1035. [PubMed: 29516601]
46. Haney CM, Loch MT and Horne WS, *Chem. Commun.*, 2011, 47, 10915–10917.
47. Smith JM, Frost JR and Fasan R, *Chem. Commun.*, 2014, 50, 5027–5030.
48. Cabezas E and Satterthwait AC, *J. Am. Chem. Soc.*, 1999, 121, 3862–3875.
49. Roice M, Johannsen I and Meldal M, *QSAR Comb. Sci.*, 2004, 23, 662–673.
50. Cantel S, Le Chevalier Isaad A, Scrima M, Levy JJ, DiMarchi RD, Rovero P, Halperin JA, D’Urso AM, Papini AM and Chorev M, *J. Org. Chem.*, 2008, 73, 5663–5674. [PubMed: 18489158]
51. Lau YH, Wu YT, de Andrade P, Galloway WRJD and Spring DR, *Nat Protoc.*, 2015, 10, 585–594. [PubMed: 25763835]
52. Haney CM, Werner HM, McKay JJ and Horne WS, *Org. Biomol. Chem.*, 2016, 14, 5768–5773. [PubMed: 27006192]
53. Tran PT, Larsen CO, Rondbjerg T, De Foresta M, Kunze MBA, Marek A, Loper JH, Boyhus LE, Knuhtsen A, Lindorff-Larsen K and Pedersen DS, *Chem. Eur. J.*, 2017, 23, 3490–3495. [PubMed: 28106305]
54. Scrima M, Le Chevalier-Isaad A, Rovero P, Papini AM, Chorev M and D’Urso AM, *Eur. J. Org. Chem.*, 2010, 2010, 446–457.
55. Kawamoto SA, Coleska A, Ran X, Yi H, Yang C-Y and Wang S, *J. Med. Chem.*, 2012, 55, 1137–1146. [PubMed: 22196480]
56. Blackwell HE and Grubbs RH, *Angew. Chem. Int. Ed.*, 1998, 37, 3281–3284.
57. Schafmeister CE, Po J and Verdine GL, *J. Am. Chem. Soc.*, 2000, 122, 5891–5892.
58. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL and Korsmeyer SJ, *Science*, 2004, 305, 1466–1470. [PubMed: 15353804]
59. Chapman RN, Dimartino G and Arora PS, *J. Am. Chem. Soc.*, 2004, 126, 12252–12253. [PubMed: 15453743]
60. Patgiri A, Jochim AL and Arora PS, *Acc. Chem. Res.*, 2008, 41, 1289–1300. [PubMed: 18630933]
61. Verdine GL and Hilinski GJ, *Methods Enzymol.*, 2012, 503, 3–33.
62. Jäger M, Nguyen H, Crane JC, Kelly JW and Gruebele M, *J. Mol. Biol.*, 2001, 311, 373–393. [PubMed: 11478867]
63. Lawrence PB, Gavrilo Y, Matthews SS, Langlois MI, Shental-Bechor D, Greenblatt HM, Pandey BK, Smith MS, Paxman R, Torgerson CD, Merrell JP, Ritz CC, Prigozhin MB, Levy Y and Price JL, *J. Am. Chem. Soc.*, 2014, 136, 17547–17560. [PubMed: 25409346]
64. Xiao Q, Becar NA, Brown NP, Smith MS, Stern KL, Draper SRE, Thompson KP and Price JL, *Org. Biomol. Chem.*, 2018, 16, 8933–8939. [PubMed: 30444518]
65. Ranganathan R, Lu KP, Hunter T and Noel JP, *Cell*, 1997, 89, 875–886. [PubMed: 9200606]
66. Yu H, Rosen MK and Schreiber SL, *FEBS Lett.*, 1993, 324, 87–92. [PubMed: 8504863]
67. Burkhard P, Stetefeld J and Strelkov SV, *Trends Cell Biol.*, 2001, 11, 82–88. [PubMed: 11166216]
68. Lupas AN and Gruber M, *Adv. Protein Chem.*, 2005, 70, 37–78. [PubMed: 15837513]
69. Woolfson DN, *Adv. Protein Chem.*, 2005, 70, 79–112. [PubMed: 15837514]
70. McLachlan AD and Stewart M, *J. Mol. Biol.*, 1975, 98, 293–304. [PubMed: 1195389]
71. O’Shea EK, Klemm JD, Kim PS and Alber T, *Science*, 1991, 254, 539–544. [PubMed: 1948029]

72. Harbury PB, Zhang T, Kim PS and Alber T, *Science*, 1993, 262, 1401–1407. [PubMed: 8248779]
73. Junius FK, Mackay JP, Bubb WA, Jensen SA, Weiss AS and King GF, *Biochemistry*, 1995, 34, 6164–6174. [PubMed: 7742321]
74. Lumb KJ and Kim PS, *Biochemistry*, 1995, 34, 8642–8648. [PubMed: 7612604]
75. Vincent TL, Green PJ and Woolfson DN, *Bioinformatics*, 2013, 29, 69–76. [PubMed: 23129295]
76. Thomson AR, Wood CW, Burton AJ, Bartlett GJ, Sessions RB, Brady RL and Woolfson DN, *Science*, 2014, 346, 485–488. [PubMed: 25342807]
77. Fletcher JM, Bartlett GJ, Boyle AL, Danon JJ, Rush LE, Lupas AN and Woolfson DN, *ACS Chem. Biol.*, 2017, 12, 528–538. [PubMed: 28026921]
78. O’Shea EK, Lumb KJ and Kim PS, *Curr. Biol.*, 1993, 3, 658–667. [PubMed: 15335856]
79. Schnarr NA and Kennan AJ, *J. Am. Chem. Soc.*, 2002, 124, 9779–9783. [PubMed: 12175236]
80. Kashiwada A, Hiroaki H, Kohda D, Nango M and Tanaka T, *J. Am. Chem. Soc.*, 2000, 122, 212–215.
81. Kiyokawa T, Kanaori K, Tajima K, Kawaguchi M, Mizuno T, Oku JI and Tanaka T, *Chem. Eur. J.*, 2004, 10, 3548–3554. [PubMed: 15252802]
82. Parry DAD, Fraser RDB and Squire JM, *J. Struct. Biol.*, 2008, 163, 258–269. [PubMed: 18342539]
83. Grigoryan G and Keating AE, *Curr. Opin. Struct. Biol.*, 2008, 18, 477–483. [PubMed: 18555680]
84. Dawson WM, Rhys GG and Woolfson DN, *Curr. Opin. Chem. Biol.*, 2019, 52, 102–111. [PubMed: 31336332]
85. Wuo MG, Mahon AB and Arora PS, *J. Am. Chem. Soc.*, 2015, 137, 11618–11621. [PubMed: 26340721]
86. Wuo MG, Hong S, Singh A and Arora PS, *J. Am. Chem. Soc.*, 2018, 140, 16284–16290. [PubMed: 30395711]
87. Lindgren J and Karlstrom A, *ChemBioChem*, 2014, 15, 2132–2138. [PubMed: 25204725]
88. Wang C, Li X, Yu F, Lu L, Jiang X, Xu X, Wang H, Lai W, Zhang T, Zhang Z, Ye L, Jiang S and Liu K, *Sci. Rep.*, 2016, 6, 32161. [PubMed: 27562370]
89. Keating AE, Malashkevich VN, Tidor B and Kim PS, *Proc. Natl. Acad. Sci. U.S.A.*, 2001, 98, 14825–14830. [PubMed: 11752430]

16/19-00 H₂N-KLPPGWEKRM**N**RS**N**GRVYYFNHITNASQFERPSG-COOH
16/32-00 H₂N-KLPPGWEKRM**N**RSSGRVYYFNHITNA**N**QFERPSG-COOH
14/30-00 H₂N-KLPPGWEK**N**MSRSSGRVYYFNHIT**N**ASQFERPSG-COOH
20/37-00 H₂N-TFVALYDYESR**N**ETDLSFKKGERLQIV**N**TEGDWVLAHSLTTGRTGYIPSNYVAPS-CONH₂




Figure 1. Sequences and structures of olefin-stapled WW variants **s16/19-o23**, **s16/32-o44** and **s14/30-o55**; triazole-stapled WW variants **s16/32-c44** and **s14/30-c44**; and olefin-stapled SH3 variant **s20/37-o44**, and their non-stapled and non-PEGylated counterparts **N** represents a PEG-modified Asn residue; the PEG oligomer(s) within each variant have the number of ethylene oxide units and the olefin, azide, alkyne, or triazole functional groups as indicated in the structural drawings.





Figure 2.

Proteolysis of (A) **16/19-00** (blue circles), **16/19-o23** (brown circles), and **s16/19-o23** (magenta circles) and of (B) **16/32-00** (blue circles), **16/32-o44** (brown circles), and **s16/32-o44** by proteinase K (17 $\mu\text{g}/\text{mL}$) at 50 μM protein concentration in 20 mM sodium phosphate buffer (pH 7) as monitored by HPLC. Data points represent the average of three replicate experiments. Solid lines represent fits of the data to a mono-exponential decay function, which was used to determine apparent proteolysis rate constants. (C) Plot of the impact of PEGylation or PEG-stapling on proteolytic resistance (as assessed by the natural logarithm of r , the ratio of apparent proteolysis rate constant for PEGylated or PEG-stapled WW variants relative to their non-stapled non-PEGylated counterparts) vs. the impact of PEGylation or PEG-stapling on WW conformational stability ($\Delta\Delta G$). Dotted line represents fit of the $\ln r$ vs. $\Delta\Delta G$ data to a linear equation. Slope = 1.55 ± 0.07 ; intercept = -0.28 ± 0.07 ; $R^2 = 0.996$.

**Figure 3.**

(A) Sequences of acidic peptide **A** and basic peptide **B**, along with disulfide-bonded parallel coiled-coil monomer **A/B**. Ribbon diagram of the published crystal structure of **A/B** (PDB ID: 1KD9), with side chains shown as sticks. *e*-position Glu residues on peptide **A** are colored blue; *g*-position Lys residues on peptide **B** are colored orange; non-polar *a*- and *d*-position residues on peptides **A** and **B** are colored dark grey. Black dotted lines indicate distances between the O ϵ 2 of Glu and N ζ of Lys within each of four *e/g'* interhelical salt bridges (i.e., Glu6/Lys1', Glu13/Lys8', Glu20/Lys15', and Glu27/Lys22'). The blue dotted line indicates the distance between O ϵ 2 of Glu27 and N ζ of Lys29', which are not involved in an interhelical salt bridge with each other (B) Sequences of acidic variant **27-c4**, basic variant **29'-c0**, disulfide-bound coiled-coil monomer **d27/29'-c40**, and its triazole-stapled counterpart **sd27/29'-c40**. **X** represents propargyl glycine and **N** represents an azide-terminated Asn-PEG, with the structures as shown.

Table 1.Folding free energies of PEGylated and PEG-stapled WW, SH3, and GCN4 variants. ^a

Protein	T _m (°C)	G (kcal/mol)	Impact of Stapling		
			G (kcal/mol)	H (kcal/mol)	-T S (kcal/mol)
16/32-00	49.2 ± 0.6	0.00 ± 0.04			
16/32-o44	54.0 ± 0.2	-0.40 ± 0.02			
s16/32-o44	71.7 ± 0.3	-1.51 ± 0.04	-1.11 ± 0.04	2.1 ± 0.9	-3.2 ± 0.9
16/32-c44	54.2 ± 0.2	-0.44 ± 0.02			
s16/32-c44	71.4 ± 0.1	-1.68 ± 0.03	-1.24 ± 0.03	8.3 ± 0.8	-9.6 ± 0.8
14/30-00	28.6 ± 0.2	0.00 ± 0.01			
14/30-o55	33.2 ± 0.1	-0.34 ± 0.01			
s14/30-o55	39.5 ± 0.6	-0.83 ± 0.05	-0.49 ± 0.05	-1.2 ± 0.9	0.7 ± 0.9
14/30-c44	30.5 ± 0.2	-0.13 ± 0.01			
s14/30-c44	41.3 ± 0.1	-0.73 ± 0.01	-0.61 ± 0.02	1.9 ± 0.4	-2.5 ± 0.4
20/37-00	61.1 ± 0.3	0.00 ± 0.02			
s20/37-o44	76.0 ± 0.8	-0.94 ± 0.06	-0.93 ± 0.07	9.9 ± 1.3	-10.8 ± 1.3
d27/29'-c40	41.1 ± 0.2	0.00 ± 0.02			
sd27/29'-c40	48.2 ± 0.1	-0.65 ± 0.01	-0.65 ± 0.02	1.3 ± 0.6	-1.9 ± 0.6
27/29'-c40	34.8	---			
s27/29'-c40	82.0 ± 0.2	---	---	---	---

^aFolding free energies for each variant are given ± std. error in kcal/mol at the melting temperature of its non-stapled non-PEGylated counterpart. WW variants **16/32-00**, **14/30-00** and SH3 variant **20/37-00** and their derivatives were analyzed at 50 μM protein concentration in 20 mM sodium phosphate buffer (pH 7). GCN4 disulfide-bound heterodimer **d27/29'-c40** and its triazole-stapled counterpart **sd27/29'-c40** were analyzed at 15 μM protein concentration in 20 mM sodium phosphate buffer (pH 7) + 4.0 M GdnHCl. GCN4 noncovalent heterodimer **27/29'-c40** and its triazole-stapled counterpart **s27/29'-c40** were analyzed at 15 μM protein concentration in 20 mM sodium phosphate buffer (pH 7) + 0.5 M GdnHCl.